A Phase 3, Multicenter, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects With Congenital Hemophilia A With Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures
Latest Information Update: 16 Mar 2022
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms CHAWI
- Sponsors Baxalta; Shire; Takeda
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 31 Jan 2021 This trial has been discontinued in Netherlands,according to European Clinical Trials Database record.
- 29 Jan 2021 This trial has been discontinued in Bulgaria according to European Clinical Trials Database record.